Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?

Key Points

• Sana Biotechnology shares fell 5.3% to about $3.48, with trading volume significantly below its average. The stock has a beta of 2.16 and remains near its 50- and 200-day moving averages.
• Analyst sentiment is generally positive but mixed: seven analysts rate the stock a Buy, while one rates it Hold and one Sell. The average price target is $9.50, well above the current price, though recent coverage included a downgrade to Sell.
• Sana reported a quarterly loss of $0.13 per share, beating the expected loss of $0.15, but analysts forecast a full-year loss of $0.56 per share. Institutional investors own 88.23% of the company, while Sana continues developing engineered-cell therapies for cancer and genetic diseases.

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) fell 5.3% on Friday . The company traded as low as $3.48 and last traded at $3.4750. Approximately 978,713 shares were traded during trading, a decline of 69% from the average daily volume of 3,114,402 shares. The stock had previously closed at $3.67.

Analyst Ratings Changes

Several research analysts have recently issued reports on SANA shares. Rodman & Renshaw began coverage on Sana Biotechnology in a research report on Monday, May 11th. They issued a "buy" rating and a $16.00 target price for the company. Wall Street Zen lowered Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. Finally, Weiss Ratings raised Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, July 23rd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $9.50.

Sana Biotechnology Price Performance

The firm has a market cap of $1.03 billion, a P/E ratio of -4.52 and a beta of 2.16. The firm's 50 day moving average is $3.35 and its 200 day moving average is $3.45.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. As a group, analysts expect that Sana Biotechnology, Inc. will post -0.56 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SANA. Rockefeller Capital Management L.P. grew its stake in shares of Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after acquiring an additional 4,088 shares during the last quarter. LRI Investments LLC purchased a new position in shares of Sana Biotechnology in the 4th quarter worth about $41,000. Walleye Capital LLC bought a new position in Sana Biotechnology in the 2nd quarter worth about $35,000. Jacobi Capital Management LLC bought a new position in Sana Biotechnology in the 4th quarter worth about $41,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Sana Biotechnology during the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source